Skip to Content

Posts tagged with "Drug Development"

  • Drug Assays

    Phenotypic Screening For the Win

    Here’s another new article in Nature Reviews Drug Discovery that (for once) isn’t titled something like “The Productivity Crisis in Drug Research: Hire Us And We’ll Consult Your Problems Away”. This one is a look back at where drugs have come from. Looking over drug approvals (259 of them) between 1999 and 2008, the au… Read More
  • Business and Markets

    Innovation and Return (Europe vs. the US)

    Here’s another look at the productivity problems in drug R&D. The authors are looking at attrition rates, development timelines, targets and therapeutic areas, and trying to find some trends to explain (or at least illuminate) what’s been going on. Their take? Attrition rates have been rising at all phases of drug development, and m… Read More
  • Business and Markets

    Drug R&D Spending Now Down (But Look at the History)

    I hate to be such a shining beacon of happiness today, but this news can’t very well be ignored, can it? For the first time ever, total drug R&D spending seems to have declined: The global drug industry cut its research spending for the first time ever in 2010, after decades of relentless increases, and… Read More
  • Academia (vs. Industry)

    What Translational Research Should Academia Do?

    We’ve talked quite a bit around here about academic (and nonindustrial) drug discovery, but those posts have mostly divided into two parts. There’s the early-stage discovery work that really gets done in some places, and then there’s the proposal for the big push into translational research by the NIH. That, broadly defined, is (a… Read More
  • Business and Markets

    Extreme Outsourcing

    My local NPR station had this report on this morning, on one-person drug companies. Can’t outsource much more than that! Here are the two companies profiled: LipimetiX and Deuteria. The former is using helical peptides to affect lipoprotein clearance, and the latter is (as you’d guess) in the deuterated-drug game, which I’ve most… Read More
  • Business and Markets

    Pfizer’s Brave New Med-Chem World

    OK, here’s how I understand the way that medicinal chemistry now works at Pfizer. This system has been coming on for quite a while now, and I don’t know if it’s been fully rolled out in every therapeutic area yet, but this seems to be The Future According to Groton: Most compounds, and most actual… Read More
  • Academia (vs. Industry)

    Maybe It Really Is That Hard?

    Here’s an interesting note from the Wall Street Journal‘s Health Blog. I can’t summarize it any better than they have: “When former NIH head Elias Zerhouni ran the $30 billion federal research institute, he pushed for so-called translational research in which findings from basic lab research would be used to develop medicine… Read More
  • Business and Markets

    Imperfect Pitch

    Venture capitalist Bruce Booth has moved his blog over to the Forbes network, and in his latest post he has some solid advice for people who are preparing to pitch him (and people like him) some ideas for a new company. It’s very sensible stuff, including the need to bring as much solid data as… Read More
  • Chemical News

    Process Chemistry Makes the Headlines

    Not a common occurrence, that. But this Wall Street Journal article goes into details on some efforts to improve the synthetic route to Viread (tenofovir) (or, to be more specific, TDF, the prodrug form of it, which is how it’s dosed). This is being funded by former president Bill Clinton’s health care foundation: The chasm… Read More
  • Chemical News

    What Medicinal Chemists Really Make

    Chemists who don’t (or don’t yet) work in drug discovery often wonder just what sort of chemistry we do over here. There are a lot of jokes about methyl-ethyl-butyl-futile, which have a bit of an edge to them for people just coming out of a big-deal total synthesis group in academia. They wonder if they’re… Read More